+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID05160480

Pilot Study Using FDA-Approved Radiotracers in Total-Body PETCT Scanning for Prostate, Breast, and Neuroendocrine Tumors

Led by University of California, Davis · Updated on 2026-10-27

9

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are exploring new ways to enhance the worlds first total-body PETCT scanner called EXPLORER. This observational study collects imaging data using one of three FDA-approved radiotracers 18F-PSMA for prostate cancer, 68Ga DOTATATE for neuroendocrine tumors, and 18F-FES for breast cancer. The study aims to better understand how these radiotracers perform in whole-body imaging for patients with these cancers. Participants will undergo a dynamic total-body PET scan lasting up to 90 minutes, followed by two static PET scans of 30 minutes each at approximately 3 hours and 6 hours after injection. Those receiving 18F-PSMA or 18F-FES will have an additional 40-minute scan around 9 hours post-injection. The study focuses on collecting detailed imaging data at these timepoints to measure radiotracer uptake. During the study, participants will be monitored during a single imaging visit lasting up to 10 hours. Researchers will measure the radiotracers avidity to assess its distribution and usefulness. Participants must be able to lie still for the scans and will be observed for safety throughout. The trial is led by the University of California, Davis, and will continue until September 2027.

CONDITIONS

Brief Title

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Research Team

C

Clinical Research Team

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here